# US 2015/0148340 A1 · Bicyclically substituted uracils and the use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148340 A1
- Document ID: US20150148340A1
- Status: Published application
- Kind: A1
- Application number: 14/399,945
- Filed: 2013-05-03
- Published: 2015-05-28
- Earliest claimed: 2012-05-09
- Assignees: Bayer Pharma Aktiengesellschaft
- Applicants: Bayer Pharma Aktiengesellschaft
- Inventors: Chantal Fürstner; Jens Ackerstaff; Alexander Straub; Heinrich Meier; Hanna Tinel; Katja Zimmermann; Adrian Tersteegen; Dmitry Zubov; Raimund Kast; Jens Schamberger; Martina Schäfer; Kirsten Börngen
- Web page: https://patentgrep.com/patent/US20150148340A1

## CPC

- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/536: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/538: ortho- or peri-condensed with carbocyclic ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.

## Claims

### Claim 1

A compound of the formula (I)
in which
R1 is hydrogen or (C1-C4)-alkyl,
R2 is a group of the formula
where
* is the attachment site to the uracil nitrogen atom,
A is —CH2—, —CH2—CH2—, —O—CH2-## or oxygen,
in which
## is the attachment site to the phenyl ring,
m is a number 0, 1 or 2,
R4 is halogen, difluoromethyl, trifluoromethyl, (C1-C4)-alkyl, difluoromethoxy, trifluoromethoxy or (C1-C4)-alkoxy,
R5A is hydrogen or deuterium,
R5B is hydrogen, deuterium or (C1-C4)-alkyl,
R6 is hydrogen or fluorine,
R7 is hydrogen or fluorine,
R8 is halogen, difluoromethyl, trifluoromethyl, (C1-C4)-alkyl or nitro,
R9 is hydrogen, halogen, difluoromethyl, trifluoromethyl, (C1-C4)-alkyl, nitro or (C1-C4)-alkylthio,
R3 is a group of the formula
where
# is the attachment site to the uracil nitrogen atom,
the ring Q is 5- to 7-membered heterocyclyl or 5- or 6-membered heteroaryl,
in which 5- to 7-membered heterocyclyl and 5- or 6-membered heteroaryl may be substituted by 1 to 4 substituents independently selected from the group of halogen, difluoromethyl, trifluoromethyl, trideuteromethyl, (C1-C6)-alkyl, (C3-C7)-cycloalkyl, oxo, hydroxyl, (C1-C4)-alkylcarbonyl, (C1-C4)-alkoxycarbonyl, aminocarbonyl and (C1-C4)-alkylsulphonyl,
in which (C1-C6)-alkyl and (C3-C7)-cycloalkyl may in turn be substituted by 1 to 3 substituents independently selected from the group of halogen, cyano, trifluoromethyl, (C3-C7)-cycloalkyl, hydroxyl, (C1-C4)-alkoxy and 4- to 7-membered heterocyclyl,
and
in which two (C1-C6)-alkyl radicals bonded to a carbon atom of 5- to 7-membered heterocyclyl and 5- or 6-membered heteroaryl, together with the carbon atom to which they are bonded, may form a 3- to 6-membered carbocycle,
R24 is halogen, (C1-C4)-alkyl or (C1-C4)-alkoxy,
n is a number 0, 1, 2 or 3,
and the salts, solvates and solvates of the salts thereof.

### Claim 2 (depends on 1)

The compound of claim 1 in which
R1 is hydrogen, methyl or ethyl,
R2 is a group of the formula
where
* is the attachment site to the uracil nitrogen atom,
A is —CH2—, —CH2—CH2—, —O—CH2-## or oxygen,
in which
## is the attachment site to the phenyl ring,
R4A is hydrogen, fluorine, chlorine, trifluoromethyl or methyl,
R4B is hydrogen, fluorine, chlorine, trifluoromethyl or methyl,
with the proviso that at least one of the R4A and R4B radicals is not hydrogen,
R5A is hydrogen,
R5B is hydrogen,
R6 is hydrogen,
R7 is hydrogen,
R8 is fluorine, chlorine, difluoromethyl, trifluoromethyl or methyl,
R9 is fluorine, chlorine, difluoromethyl, trifluoromethyl or methyl,
R3 is a group of the formula
where
# is the attachment site to the uracil nitrogen atom,
E is CR11 or N,
in which
R11 is hydrogen, (C1-C4)-alkyl, (C3-C7)-cycloalkyl or aminocarbonyl,
E2 is CR12 or N,
in which
R12 is hydrogen, (C1-C4)-alkyl or (C3-C7)-cycloalkyl,
E3 is NR14 or S,
in which
R14 is hydrogen, (C1-C4)-alkyl or (C3-C7)-cycloalkyl,
G1 is C═O or SO2,
G2 is CR16AR16B, NR17, O or S,
in which
R16A is hydrogen, fluorine, (C1-C4)-alkyl or hydroxyl,
R16B is hydrogen, fluorine, chlorine, (C1-C4)-alkyl or trifluoromethyl,
or
R16A and R16B together with the carbon atom to which they are bonded form a 3- to 6-membered carbocycle,
R17 is hydrogen, (C1-C6)-alkyl, (C3-C7)-cycloalkyl or (C1-C4)-alkoxycarbonyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3 substituents independently selected from the group of fluorine, trifluoromethyl, cyano, (C3-C7)-cycloalkyl, hydroxyl, trifluoromethoxy, (C1-C4)-alkoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl,
G3 is CR18AR18B, NR19, O or S,
in which
R18A is hydrogen, fluorine, (C1-C4)-alkyl or hydroxyl,
R18B is hydrogen, fluorine, chlorine, (C1-C4)-alkyl or trifluoromethyl,
or
R18A and R18B together with the carbon atom to which they are bonded form a 3- to 6-membered carbocycle,
R19 is hydrogen, (C1-C6)-alkyl, (C3-C7)-cycloalkyl or (C1-C4)-alkoxycarbonyl,
in which (C1-C6)-alkyl may be substituted by 1 to 3 substituents independently selected from the group of fluorine, trifluoromethyl, cyano, (C3-C7)-cycloalkyl, hydroxyl, trifluoromethoxy, (C1-C4)-alkoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl,
G4 is CH2, C═O or SO2,
K1 is CH2 or O,
K2 is CH2 or O,
with the proviso that only one of the K1 and K2 groups is O,
D1, D2, D3 and D4 are each independently CR23 or N,
in which
R23 is hydrogen, halogen, (C1-C6)-alkyl or (C3-C7)-cycloalkyl,
with the proviso that not more than 2 of the D1, D2, D3 and D4 groups are N,
R24 is fluorine or methyl,
n is a number 0 or 1,
R10 is (C1-C4)-alkyl or (C3-C7)-cycloalkyl,
in which (C1-C4)-alkyl may be substituted by 1 or 2 substituents independently selected from the group of fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxyl, methoxy, ethoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl,
R13 is hydrogen, (C1-C4)-alkyl or (C3-C7)-cycloalkyl,
R15 is hydrogen, (C1-C6)-alkyl or (C3-C7)-cycloalkyl,
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents independently selected from the group of fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxyl, methoxy, ethoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl,
R20 is hydrogen, (C1-C6)-alkyl, (C3-C7)-cycloalkyl or (C1-C4)-alkylcarbonyl,
in which (C1-C6)-alkyl may be substituted by 1 or 2 substituents independently selected from the group of fluorine, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxyl, methoxy, ethoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl,
R21 is hydrogen, (C1-C6)-alkyl, (C3-C7)-cycloalkyl or (C1-C4)-alkylsulphonyl,
R22A is hydrogen or (C1-C4)-alkyl,
R22B is hydrogen or (C1-C4)-alkyl,
or
R22A and R22B together with the carbon atom to which they are bonded form a carbonyl group,
and the salts, solvates and solvates of the salts thereof.

### Claim 3 (depends on 1)

The compound of claim 1 in which
R1 is hydrogen,
R2 is a group of the formula
where
* is the attachment site to the uracil nitrogen atom,
A is —CH2—,
R4A is chlorine or trifluoromethyl,
R4B is hydrogen,
R3 is a group of the formula
where
# is the attachment site to the uracil nitrogen atom,
E1 is CR11
in which
R11 is hydrogen,
E2 is N,
G1 is C═O,
G2 is CR16AR16B, NR17, O or S,
in which
R16A is hydrogen, fluorine, methyl or hydroxyl,
R16B is hydrogen, fluorine, methyl or trifluoromethyl,
or
R16A and R16B together with the carbon atom to which they are bonded form a cyclopropyl ring,
R17 is hydrogen, (C1-C4)-alkyl or (C3-C5)-cycloalkyl,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents independently selected from the group of fluorine, trifluoromethyl, cyano, cyclopropyl, cyclobutyl, hydroxyl, trifluoromethoxy, methoxy, ethoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl,
R24 is hydrogen or fluorine,
R10 is (C1-C4)-alkyl,
R15 is hydrogen, methyl or ethyl,
in which methyl and ethyl may be substituted by 1 substituent selected from the group of fluorine, trifluoromethyl and cyclopropyl,
and the salts, solvates and solvates of the salts thereof.

### Claim 4 (depends on 1)

The compound of claim 1 in which
R1 is hydrogen,
R2 is a group of the formula
where
* is the attachment site to the uracil nitrogen atom,
R5A is hydrogen,
R5B is hydrogen,
R6 is hydrogen,
R7 is hydrogen,
R8 is fluorine, chlorine or trifluoromethyl,
R9 is fluorine, chlorine, trifluoromethyl or methyl,
R3 is a group of the formula
where
# is the attachment site to the uracil nitrogen atom,
E1 is CR11
in which
R11 is hydrogen,
E2 is N,
G1 is C═O,
G2 is CR16AR16B, NR17, O or S,
in which
R16A is hydrogen, fluorine, methyl or hydroxyl,
R16B is hydrogen, fluorine, methyl or trifluoromethyl,
or
R16A and R16B together with the carbon atom to which they are bonded form a cyclopropyl ring,
R17 is hydrogen, (C1-C4)-alkyl or (C3-C5)-cycloalkyl,
in which (C1-C4)-alkyl may be substituted by 1 to 3 substituents independently selected from the group of fluorine, trifluoromethyl, cyano, cyclopropyl, cyclobutyl, hydroxyl, trifluoromethoxy, methoxy, ethoxy, azetidinyl, oxetanyl, tetrahydrofuranyl and pyrrolidinyl,
R24 is hydrogen or fluorine,
R10 is (C1-C4)-alkyl,
R15 is hydrogen, methyl or ethyl,
in which methyl and ethyl may be substituted by 1 substituent selected from the group of fluorine, trifluoromethyl and cyclopropyl,
and the salts, solvates and solvates of the salts thereof.

### Claim 5 (depends on 1)

A process for preparing compounds of the formula (I) of claim 1, comprising:
[A] reacting a compound of the formula (II)
in which
R1A is (C1-C4)-alkyl,
T1 is (C1-C4)-alkyl,
T2 is (C1-C4)-alkyl,
in an inert solvent, optionally in the presence of a suitable base, with a compound of the formula (III)
H2N—R3 (III)
in which R3 is as defined in claim 1
to give a compound of the formula (IV)
in which R1A and R3 are each as defined above,
reacting the compound of formula (IV) in an inert solvent, in the presence of a suitable base, with a compound of the formula (V)
X1—R2 (V)
in which R2 is as defined in claim 1 and
X1 is hydroxyl or a suitable leaving group, especially chlorine, bromine or iodine
to give a compound of the formula (I-1)
in which R1A, R2 and R3 are each as defined above,
or
[B] converting a compound of the formula (VI)
in which R1A and T1 are each as defined above,
and
T3 is (C1-C4)-alkyl
in an inert solvent or else without solvent with a compound of the formula (III) to a compound of the formula (VII)
in which R1A, R3 and T3 are each as defined above,
reacting the compound of formula (VII) in an inert solvent with chlorosulphonyl isocyanate to give a compound of the formula (IV) and
converting the compound of formula (IV) analogously to process [A] to a compound of the formula (I-1),
or
[C] reacting a compound of the formula (VIII)
in which R2 is as defined in claim 1
in an inert solvent with a compound of the formula (IX)
in which R1A and T1 are each as defined above and
T5 is (C1-C4)-alkyl
and cyclized in the presence of a suitable base to give a compound of the formula (X)
in which R1A and R2 are each as defined above,
reacting the compound of formula (X) in an inert solvent, in the presence of a suitable catalyst and a suitable base, with a compound of the formula (XI)
in which R3 is as defined above
and
T6 is hydrogen, (C1-C4)-alkyl, or the two T6 radicals together form a —C(CH3)2—C(CH3)2— bridge
to give a compound of the formula (I-1),
or
[D] hydrolysing a compound of the formula (I-1) in an inert solvent in the presence of a suitable acid or base to give a compound of the formula (I-2)
in which R2 and R3 are each as defined in claim 1 and
R1B is hydrogen,
any protecting groups are detached and/or the compounds of the formulae (I-1) and (I-2) are, optionally, converted with the appropriate (i) solvents and/or (ii) bases or acids to the solvates, salts and/or solvates of the salts thereof.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 one or more inert nontoxic pharmaceutically suitable excipients.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, at least one further active ingredients selected from the group consisting of a calcium antagonist, an angiotensin AII antagonist, an ACE inhibitor, a vasopeptidase inhibitor, an endothelin antagonist, a renin inhibitor, an alpha-receptor blocker, a beta-receptor blocker, a mineralocorticoid receptor antagonist, a rho-kinase inhibitor, a diuretic, a kinase inhibitor, a matrix metalloprotease inhibitor, a stimulator and/or activator of soluble guanylate cyclase and a phosphodiesterase inhibitor.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A method for treatment and/or prophylaxis of heart failure, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, kidney failure, nephropathy, fibrotic disorders of the internal organs and dermatological fibroses comprising administering to a humans or and animals an effective amount of at least one compound of claim 1.

### Claim 12 (depends on 8)

A method for treatment and/or prophylaxis of heart failure, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, kidney failure, nephropathy, fibrotic disorders of the internal organs and dermatological fibroses comprising administering to a human or animal an effective amount of the pharmaceutical composition of claim 8.
